Industry news: patients with highly active MS will now have access to cladribine tablets without the additional requirement of a gadolinium-enhanced MRI, following review from NICE.
Category: MS
EMA approves interferon beta treatments, including Rebif (interferon beta-1a), for relapsing MS patients during pregnancy and breastfeeding
News from Merck
Interferon Beta Treatments Receive Positive CHMP Opinion for Use in Relapsing Forms of Multiple Sclerosis (MS) During Pregnancy and Breastfeeding
News about Interferon Beta Treatments
New data from Biogen reinforce long-term benefits of Tecfidera® (Dimethyl Fumarate) over 10 years
News from Biogen at #ECTRIMS19
New Real-World Data Support Long-Term Efficacy and Safety Profile of MAVENCLAD®
News of Mavenclad from #ECTRIMS19
PathMaker Neurosystems is Named as Recipient of France’s Top Prize for Innovation
News from PathMaker Neurosystems
NHS Ayrshire & Arran launch campaign on World MS Day calling on people with MS to seek regular support from services
Campaign to encourage interaction of PwMS with services
NHS England partners with Merck on a commercial agreement that allows people with MS in England immediate access to cladribine tablets (Mavenclad®)
News from Merck
The Missing Pieces: Identifying the gaps in care and conversations in MS
Developed and funded by Sanofi Genzyme
